A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer

Randolph Stuart Marks, David L. Graham, Jeff A Sloan, Shauna Hillman, Steven Fishkoff, James E. Krook, Scott Heitaka Okuno, James A. Mailliard, Tom R. Fitch, Ferdinand Addo

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.

Original languageEnglish (US)
Pages (from-to)336-337
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number4
DOIs
StatePublished - Aug 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Proxy
Intravenous Infusions
Therapeutics
dolastatin 15
cemadotin
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. / Marks, Randolph Stuart; Graham, David L.; Sloan, Jeff A; Hillman, Shauna; Fishkoff, Steven; Krook, James E.; Okuno, Scott Heitaka; Mailliard, James A.; Fitch, Tom R.; Addo, Ferdinand.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 4, 08.2003, p. 336-337.

Research output: Contribution to journalArticle

Marks, Randolph Stuart ; Graham, David L. ; Sloan, Jeff A ; Hillman, Shauna ; Fishkoff, Steven ; Krook, James E. ; Okuno, Scott Heitaka ; Mailliard, James A. ; Fitch, Tom R. ; Addo, Ferdinand. / A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2003 ; Vol. 26, No. 4. pp. 336-337.
@article{ee8864f218c8495abc2a674f769c4929,
title = "A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer",
abstract = "A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.",
author = "Marks, {Randolph Stuart} and Graham, {David L.} and Sloan, {Jeff A} and Shauna Hillman and Steven Fishkoff and Krook, {James E.} and Okuno, {Scott Heitaka} and Mailliard, {James A.} and Fitch, {Tom R.} and Ferdinand Addo",
year = "2003",
month = "8",
doi = "10.1097/00000421-200308000-00005",
language = "English (US)",
volume = "26",
pages = "336--337",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer

AU - Marks, Randolph Stuart

AU - Graham, David L.

AU - Sloan, Jeff A

AU - Hillman, Shauna

AU - Fishkoff, Steven

AU - Krook, James E.

AU - Okuno, Scott Heitaka

AU - Mailliard, James A.

AU - Fitch, Tom R.

AU - Addo, Ferdinand

PY - 2003/8

Y1 - 2003/8

N2 - A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.

AB - A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.

UR - http://www.scopus.com/inward/record.url?scp=10744230054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744230054&partnerID=8YFLogxK

U2 - 10.1097/00000421-200308000-00005

DO - 10.1097/00000421-200308000-00005

M3 - Article

C2 - 12902880

AN - SCOPUS:10744230054

VL - 26

SP - 336

EP - 337

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 4

ER -